Boston Scientific Corp.
- BSX · NYSE
- Surgical & Medical Instruments & Apparatus
- Marlborough, MA
- 59,000 employees
- CIK 0000885725
Updated from SEC filings through
Top things to know
Executives
- Mike Mahoney Chairman and chief executive officer, Boston Scientific 8-K, 2026-10-28
-
Michael F. Mahoney Chairman, President & CEO 4, 2026-08-05 -
Jonathan Monson EVP and CFO 4, 2026-08-11 -
Miriam O'Sullivan SVP, Chief HR Officer 4, 2026-02-18 - Emily M. Woodworth Senior Vice President, Global Controller and Chief Accounting Officer 10-K, 2026-02-17
- Padraig Andrew O'Connor EVP, Global Operations 4, 2026-09-03
What leadership is saying
“This has been a challenging year for Boston Scientific and I’m proud of how our global teams have responded, particularly to the cybersecurity incident, working with urgency and resilience to restore operations and continue supporting customers and patients”
Earnings press release (8-K Ex. 99.1), filed October 28, 2026
Boston Scientific Corp is a U.S. public company in surgical & medical instruments & apparatus (SIC 3841), headquartered in Marlborough, MA. It trades as BSX on NYSE. Revenue was $20.1B in the fiscal year ending December 31, 2025, +19.9% from the year before. It reported about 59,000 employees. Mike Mahoney is Chairman and chief executive officer, Boston Scientific.
Five-year financials
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $20.1B 10-K, 2026-02-17 | $16.7B 10-K, 2026-02-17 | $14.2B 10-K, 2026-02-17 | $12.7B 10-K, 2025-02-18 | $11.9B 10-K, 2024-02-20 |
| Operating income | $3.6B 10-K, 2026-02-17 | $2.6B 10-K, 2026-02-17 | $2.3B 10-K, 2026-02-17 | $1.6B 10-K, 2025-02-18 | $1.2B 10-K, 2024-02-20 |
| SG&A | $6.9B 10-K, 2026-02-17 | $6.0B 10-K, 2026-02-17 | $5.2B 10-K, 2026-02-17 | $4.5B 10-K, 2025-02-18 | $4.4B 10-K, 2024-02-20 |
| Net income | $2.9B 10-K, 2026-02-17 | $1.8B 10-K, 2026-02-17 | $1.6B 10-K, 2026-02-17 | $698M 10-K, 2025-02-18 | $1.0B 10-K, 2024-02-20 |
Annual figures from XBRL in each company's own filings. Click a figure to open the filing. SG&A marked derived is general and administrative plus selling and marketing.
Leadership and board
| Name | Title | Source |
|---|---|---|
| Mike Mahoney | Chairman and chief executive officer, Boston Scientific | 8-K, 2026-10-28 |
| Michael F. Mahoney | Chairman, President & CEO | 4, 2026-08-05 |
| Jonathan Monson Chief Financial Officer | EVP and CFO | 4, 2026-08-11 |
| Jonathan R. Monson | Named in proxy bio: Executive Vice President and Chief Financial Officer | DEF 14A, 2026-03-18 |
 Joseph M. Fitzgerald | Named in proxy bio: Executive Vice President and Group President, Cardiovascular | DEF 14A, 2026-03-18 |
| Padraig A. O'Connor | Named in proxy bio: Executive Vice President, Global Operations | DEF 14A, 2026-03-18 |
| Miriam O'Sullivan Senior Vice President and Chief Human ... | SVP, Chief HR Officer | 4, 2026-02-18 |
| Emily M. Woodworth | Senior Vice President, Global Controller and Chief Accounting Officer | 10-K, 2026-02-17 |
| Padraig Andrew O'Connor | EVP, Global Operations | 4, 2026-09-03 |
| Emily Woodworth | SVP, Global Controller and CAO | 4, 2026-08-12 |
| Joseph Michael Fitzgerald | EVP & Group Pres, Cardiology | 4, 2026-08-03 |
 Vance R. Brown Executive Vice President, General Counsel and Corporate Secretary at Boston Scientific | EVP, GC and Corp. Secretary | 4, 2026-02-18 |
| Cheryl Pegus | Director | 10-K, 2026-02-17 |
| David Habiger | Director | 10-K, 2026-02-17 |
| David S. Wichmann | Director | 10-K, 2026-02-17 |
| Edward J. Ludwig | Director | 10-K, 2026-02-17 |
What Boston Scientific Corp does
Boston Scientific Corporation is a global developer, manufacturer and marketer of medical devices that are used in a broad range of interventional medical specialties. Our mission is to transform lives through innovative medical solutions that improve the health of patients around the world.
Item 1. Business, 10-K for the year ending December 31, 2025
Shares and governance
| Shares outstanding | 1.45 billion (as of October 29, 2026) | 10-Q, November 2, 2026 |
|---|---|---|
| Public float | $159B (as of June 30, 2025) | 10-K, February 17, 2026 |
| Reportable segments | 2 (period ending September 30, 2026) | 10-Q, November 2, 2026 |
| Latest proxy statement | Meeting March 18, 2026 (filed March 18, 2026) | DEF 14A, March 18, 2026 |
| Auditor | Ernst & Young LLP (Boston, Massachusetts) | Latest 10-K |
Insider trades
Open-market buys and sales by officers and directors, from Forms 4 and 5. One row per filing.
| Date | Insider | Trade | Shares | Value | Source |
|---|---|---|---|---|---|
| August 25, 2026 | Susan E. Morano Director | Buy | 2,040 | $100K | Form 4, August 26, 2026 |
| August 5, 2026 | David C. Habiger Director | Buy | 2,100 | $100K | Form 4, August 7, 2026 |
| August 4, 2026 | David C. Habiger Director | Buy | 1,182 | $57K | Form 4, August 5, 2026 |
| August 3, 2026 | Michael F. Mahoney Chairman, President & CEO | Buy | 186,240 | $9.0M | Form 4, August 5, 2026 |
| July 31, 2026 | Edward J. Ludwig Director | Buy | 5,000 | $227K | Form 4, August 3, 2026 |
| May 20, 2026 | Cheryl Pegus Director | Buy | 1,770 | $100K | Form 4, May 21, 2026 |
| May 20, 2026 | Edward J. Ludwig Director | Buy | 3,580 | $203K | Form 4, May 21, 2026 |
| May 20, 2026 | David C. Habiger Director | Buy | 4,450 | $251K | Form 4, May 21, 2026 |
Recent 8-K events
- 8-K filed 2026-10-28
- Item 2.02 Results of operations and financial condition (earnings release)
- 8-K filed 2026-10-07
- Item 5.02 Departure or appointment of directors or officers; compensation
- Item 8.01 Other events
- 8-K filed 2026-09-23
- Item 5.02 Departure or appointment of directors or officers; compensation
- 8-K filed 2026-09-08
- Item 1.05 Material cybersecurity incident
- 8-K filed 2026-08-26
- Item 8.01 Other events
- 8-K filed 2026-07-29
- Item 2.02 Results of operations and financial condition (earnings release)
- 8-K filed 2026-07-27
- Item 2.05 Costs associated with exit or disposal activities (restructuring)
- 8-K filed 2026-05-18
- Item 8.01 Other events
- 8-K filed 2026-05-18
- Item 8.01 Other events
- 8-K filed 2026-05-05
- Item 5.03 Amendments to articles or bylaws; change in fiscal year
- Item 5.07 Submission of matters to a vote of security holders
Frequently asked questions about Boston Scientific Corp
- What does Boston Scientific Corp do?
- In its own words, from Item 1 of its 10-K: "Boston Scientific Corporation is a global developer, manufacturer and marketer of medical devices that are used in a broad range of interventional medical specialties. Our mission is to transform lives through innovative medical solutions that improve the health of patients around the world."
- What is Boston Scientific Corp's revenue?
- $20.1B for the fiscal year ending December 31, 2025, from its 10-K filed February 17, 2026.
- Is Boston Scientific Corp profitable?
- Boston Scientific Corp reported net income of $2.9B for the fiscal year ending December 31, 2025.
- How many employees does Boston Scientific Corp have?
- About 59,000 as of December 31, 2025, as stated in its annual report.
- Who is the CEO of Boston Scientific Corp?
- Mike Mahoney, Chairman and chief executive officer, Boston Scientific, as named in a 8-K filed October 28, 2026.
- Who is the CFO of Boston Scientific Corp?
- Jonathan Monson, EVP and CFO, as named in a 4 filed August 11, 2026.
- Where is Boston Scientific Corp headquartered?
- Marlborough, MA.
- What is Boston Scientific Corp's stock ticker?
- BSX on NYSE.
- What industry is Boston Scientific Corp in?
- Surgical & Medical Instruments & Apparatus, SIC code 3841.
- What is Boston Scientific Corp's website?
- bostonscientific.com. Investor relations: https://investors.bostonscientific.com/.
- When does Boston Scientific Corp report earnings next?
- February 10, 2027. Source: estimate_8k_pattern.
- Is Boston Scientific Corp a public company?
- Yes. Boston Scientific Corp files with the SEC under CIK 0000885725 and trades as BSX.
- Who audits Boston Scientific Corp?
- Ernst & Young LLP, Boston, Massachusetts, as named in its latest annual report (10-K).
- How many shares of Boston Scientific Corp are outstanding?
- 1.45 billion shares as of October 29, 2026, from its 10-Q filed November 2, 2026.
- What is Boston Scientific Corp's public float?
- $159B as of June 30, 2025, as reported on the cover of its 10-K filed February 17, 2026.
- How many business segments does Boston Scientific Corp report?
- 2 reportable segments for the period ending September 30, 2026, from its 10-Q filed November 2, 2026.
- When is Boston Scientific Corp's annual shareholder meeting?
- March 18, 2026, per its proxy statement (DEF 14A) filed March 18, 2026.
- Have Boston Scientific Corp insiders traded stock recently?
- Since July 1, 2025, officers and directors reported 12 open-market sales worth about $47.7M and 8 purchases worth about $10.0M on Forms 4 and 5. The most recent: Susan E. Morano (Director) bought 2,040 shares on August 25, 2026.